Free Trial
NASDAQ:SBFM

Sunshine Biopharma Q3 2025 Earnings Results & Report

Sunshine Biopharma logo
$2.61 -0.09 (-3.33%)
As of 03:02 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Sunshine Biopharma missed analyst expectations on both earnings and revenue in its Q3 2025 results, released November 13, 2025. The company reported EPS of -$38.00 versus the -$26.00 consensus estimate, while revenue of $9.42 million fell short of the $11.10 million estimate by $1.68 million.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens

Sunshine Biopharma EPS Results

Actual EPS
-$38.00
Consensus EPS
-$26.00
Beat/Miss
Missed by -$12.00
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 6 quarters

Sunshine Biopharma Revenue Results

Actual Revenue
$9.42 million
Expected Revenue
$11.10 million
Beat/Miss
Missed by -$1.68 million
YoY Revenue Growth
N/A

Conference Call Resources

Sunshine Biopharma Q3 2025 Earnings FAQ

Sunshine Biopharma (NASDAQ:SBFM) reported earnings of -$38.00 per share for Q3 2025, missing the consensus estimate of -$26.00. The report was announced on Thursday, November 13, 2025.

Sunshine Biopharma reported revenue of $9.42 million for Q3 2025, against a consensus estimate of $11.10 million.

Sunshine Biopharma Earnings Headlines

Sunshine Biopharma (SBFM) Set to Post Quarterly Earnings on Thursday
Sunshine Biopharma (SBFM) AI Stock Analysis
A Nasdaq drone company just landed a deal with a Philippine billionaire's group
A Nasdaq-listed drone company just signed an exclusive agreement with Prime Strategic Holdings, part of billionaire Enrique Razon Jr.'s business empire. The Razon Group spans ports, energy, mining, utilities and infrastructure, and its affiliated port operator generated over $3.2 billion in 2025 revenue. The deal lays the groundwork for drone manufacturing in the Philippines, with potential expansion across Southeast Asia. The company was also selected for a five-year Canadian Armed Forces contract covering 100 systems, with options for up to 4,900 more. It supplies the U.S. Army, holds a U.S. Air Force Special Operations Command contract, and recently announced a $10 million strategic investment from Unusual Machines.tc pixel
See More Sunshine Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sunshine Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sunshine Biopharma and other key companies, straight to your email.

About Sunshine Biopharma

Sunshine Biopharma (NASDAQ:SBFM) is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for cancer and other medical conditions. Its lead oncology candidate, Adva-27a, is an investigational small-molecule drug designed to inhibit topoisomerase II, an enzyme involved in cancer-cell replication. The company has studied the compound in preclinical models, including models of breast cancer and multidrug-resistant tumors.

In addition to its drug-development activities, Sunshine Biopharma has expanded into the pharmaceutical products business through its Canadian operations. The company has been associated with the distribution and commercialization of prescription and over-the-counter products in Canada, including generic medicines and other healthcare products.

Sunshine Biopharma is headquartered in Canada and has conducted its pharmaceutical and biotechnology activities primarily through its Canadian operations. The company has identified Steve Slilaty as its chief executive officer and has traded on the Nasdaq Capital Market under the symbol SBFM. Its business combines the development of proprietary oncology candidates with pharmaceutical product commercialization.

View Sunshine Biopharma Profile